Molecular Diagnosis of Cancer: Methods and ProtocolsJoseph E. Roulston, John M. S. Bartlett Springer Science & Business Media, 2008 M02 1 - 394 pages We are currently experiencing a fundamental shift in the way in which we approach the characterization of cancer. Never before has the make up of cancer tissues and individual cells been so exhaustively researched and char- terized. We are now capable of producing molecular “fingerprints” that ch- acterize the expression of all known and unknown genes within tumors and their surrounding tissues. More than 30,000 different genes may be measured in each patient’s tumor in a single experiment. Simultaneously, novel therapies that exploit the molecular roadmap have been developed and are now being offered to patients. These novel agents, such as Glivec, Herceptin, Iressa, and others, specifically target individual genes within tumors and can produce d- matic responses in some patients. These drugs are only the forerunners of a coming tidal wave of novel therapeutics that individually target specific m- ecules within cancer cells—more than 300 such agents are currently in phase I or II clinical trials. This is an exciting time for cancer specialists and patients alike. However, if we have learned anything from the past 50 or more years of research into cancer, it is that Lord Beaverbrook, in founding the British national health service in the 1950s, was frighteningly prescient when he defined the primary goal of health care to be “Diagnosis, Diagnosis, Diag- sis. ” Now, more than ever, it is essential that appropriate diagnostic methods and approaches are applied to the selection of patients for treatment. |
Contents
Assessment of Predictive Values of Tumor Markers | 13 |
Anthony Rhodes and Diana M Barnes 4 Extraction of Nucleic Acid Templates | 29 |
Microdissection and Extraction of DNA From Archival Tissue | 71 |
Fluorescence In Situ Hybridization for BCRABL | 103 |
Marie Jarosova 12 Molecular Characterization of Human Papillomaviruses | 145 |
TP53 Mutation Detection by SSCP and Sequencing | 191 |
Bone Marrow Biopsies | 209 |
Theory and Methods | 217 |
Determination of Cyclin D1 Expression by Quantitative RealTime | 277 |
and Its Splice Variants by RTPCR | 297 |
W Nicol Keith and Aileen J Monaghan | 311 |
Identification of TP53 Mutations in Human Cancers | 323 |
Detection of Kras Mutations by a Microelectronic DNA Chip | 337 |
Ekaterina Pestova Kim Wilber and Walter King | 355 |
Tissue Microarrays | 377 |
391 | |
The Diagnostic and Prognostic Significance of the Methylation | 251 |
Quantitative Analysis of PRAME for Detection of Minimal | 267 |
Other editions - View all
Molecular Diagnosis of Cancer: Methods and Protocols Joseph E. Roulston,John M. S. Bartlett No preview available - 2004 |
Molecular Diagnosis of Cancer: Methods and Protocols Joseph E. Roulston,John M. S. Bartlett No preview available - 2010 |
Common terms and phrases
agarose aliquot amplification analysis approx array assay breast cancer buffer Cancer Res carcinoma cDNA cell lines Centrifuge chromosome CISH Clin clinical colorectal colorectal cancer containing Coplin jar copy number coverslip cyclin D1 denaturation DEPC detection diagnostic digestion disease distilled water DNA Extraction EBV DNA EDTA enzyme ethanol evaluation exon FISH fluorescence fragments gene genetic HER2 human human papillomavirus hybridization immunohistochemistry Incubate K-ras labeled laboratories leukemia lymphoma mantle cell lymphoma markers master mix method methylation microarray microcentrifuge tube microsatellite molecular mutations Note nucleic acid oligonucleotide oncogene overexpression Pathol PCR product pellet pipet plasma polymerase chain reaction PRAME primer probe prognostic protein protocol reagents receptor RNase room temperature sample scoring sensitivity sequence signal situ hybridization slides solution specific specimens staining sterile stored supernatant target telomerase tion tissue translocation Tris-HCl tumor types vortex Vysis wash water bath